Track record · closed signal

MBX Biosciences, Inc. (MBX) — closed signal from January 12, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 12, 2026.

Predicted vs. what happened

MBX price · publication thesis → realized outcomesplit-adjusted
$33.78 Published $42.23 Target $32.86 Window close $44.89 Peak
$31.50 – $34.00Entry zone — fair-value band
$33.78Published — price the day we called it
$42.23Target — the price the thesis aimed for
$44.89Peak — highest point inside the window, not a realized return
$32.86Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 2 days.

Peak price
$44.89
peak on January 15, 2026 — not a realized return
Peak gain
+32.9%
peak, from the publication price
Window close
$32.86
end-of-window price, context only
Days to target
2
Window
January 12, 2026 – April 12, 2026

The thesis — published January 12, 2026

Predicted growth
+25%
over the measurement window
Target price
$42.23
the price the thesis aimed for
Entry zone
$31.50 – $34.00
the fair-value band we waited for
Price at publication
$33.78
published January 12, 2026
Confidence
72%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

MBX is a risky but potentially high-reward healthcare stock. They announced 2026 program steps and said they have about $373.7M, which could fund them into 2029 and ease the need to raise money soon. The share price has fallen, so consider small positions and wait for signs buyers return after the company update.

Primary drivers

  • Conference update keeps focus on drug plans and timelines
  • Cash through 2029 lowers chance they must raise money soon
  • Clinical programs can cause big price moves if news improves
  • Deeply sold shares can bounce quickly when demand returns

How it played out

MBX: target reached in 2 days

Lyra published MBX at $33.78 on January 12, 2026, with expected growth of 25%. The thesis pointed to 2026 program steps, about $373.7M in cash, funding into 2029, clinical programs that could move the stock, and deeply sold shares that could bounce if demand returned.

Inside the window, MBX rose above the $42.23 target. It peaked at $44.89 on January 15, 2026, with a 32.9% gain, and reached the target in 2 days. By April 12, 2026, it ended at $32.86. The thesis played out quickly, even though the later close gave back that move.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MBX signals